Bridgehead Consulting completes due diligence study for Tyrell Inc
18 May 2008
Bridgehead International recently completed an independent due
diligence study on Tyrell Inc. as part of a fundraising programme.
Tyrell Inc. is a medical technology company focused on the development
of medical devices for the treatment of skin lesions.
Comprised of experts from both the medical and consumer products
industries, Tyrell develops and market new, non-prescription medical
devices based on its proprietary ClearPoint Technology.
The first of these is Zeno, for over-the-counter treatment of acne.
Zeno was given FDA clearance as a Class II medical device in June 2005.
A CE mark in Europe was granted in 2006 and the product is also approved
in Canada, Japan and a number of other Asian markets. Further products
based on the ClearPoint technology are in development.
Paul Tufano, Chief Financial Officer of Tyrell said: "As an
international medical device company which has launched multiple devices
spanning numerous indications, we often have difficulty finding a
consultancy firm that has the depth of technical expertise and market
resources to assess the landscape with which we work. Our engagement of
Bridgehead has proven to be very valuable to the growth and operation of
our business. Their assessment of the competitive landscape, our product
strategy and the intellectual property environment has driven many
important changes to the way we have managed the success of our